Functionalization of matrices by cyclically stretched osteoblasts through matrix targeting of VEGF

Biomaterials

Volumn 31, Issue 25, 2010, Pages 6477-6484

  Faure, Céline ^a   Vico, Laurence ^a   Tracqui, Philippe ^b   Laroche, Norbert ^a   Vanden Bossche, Arnaud ^a   Linossier, Marie Thérèse ^a   Rattner, Aline ^a   Guignandon, Alain ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

Cyclic strain; Endothelial cells; Osteoblasts; VEGF

Indexed keywords

ANGIOGENESIS; ANGIOGENIC FACTOR; APOPTOTIC; CYCLIC STRAIN; CYCLIC STRETCH; EXTRACELLULAR MATRICES; FUNCTIONALIZATIONS; FUNCTIONALIZED; HIGH FREQUENCY; IN-VITRO; IN-VIVO; LOW FREQUENCY; MATRIX; METALLOPROTEINASES; MICROVASCULAR; SILICONE MEMBRANE; TISSUE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR;

BLOOD VESSEL PROSTHESES; CYTOLOGY; ENZYME ACTIVITY; OSTEOBLASTS; SELF ASSEMBLY; SILICONES; TISSUE;

ENDOTHELIAL CELLS;

CASPASE 3; PIGMENT EPITHELIUM DERIVED FACTOR; SILICONE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; BIOMATERIAL; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; VASCULOTROPIN A;

ANGIOGENESIS; APOPTOSIS; ARTICLE; ARTIFICIAL MEMBRANE; CELL MIGRATION; CELL STRETCHING; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MECHANICAL STRESS; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN SECRETION; ANIMAL; CELL CULTURE; CELL LINE; CELL MOTION; CHEMISTRY; CHILD; CYTOLOGY; GENETICS; MECHANICS; METABOLISM; MOUSE; NUDE MOUSE;

ANIMALS; APOPTOSIS; BIOCOMPATIBLE MATERIALS; CELL LINE; CELL MOVEMENT; CELLS, CULTURED; CHILD; DOWN-REGULATION; ENDOTHELIAL CELLS; EYE PROTEINS; HUMANS; MECHANICAL PHENOMENA; MICE; MICE, NUDE; NEOVASCULARIZATION, PHYSIOLOGIC; NERVE GROWTH FACTORS; OSTEOBLASTS; SERPINS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953961101     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.05.011     Document Type: Article

References (45)

1. Rubin C., Turner A.S., Bain S., Mallinckrodt C., McLeod K. Anabolism. Low mechanical signals strengthen long bones. Nature 2001, 412(6847):603-604.
2. Schriefer J.L., Warden S.J., Saxon L.K., Robling A.G., Turner C.H. Cellular accommodation and the response of bone to mechanical loading. J Biomech 2005, 38(9):1838-1845.
3. Jaasma M.J., Jackson W.M., Tang R.Y., Keaveny T.M. Adaptation of cellular mechanical behavior to mechanical loading for osteoblastic cells. J Biomech 2007, 40(9):1938-1945.
4. Hoberg M., Gratz H.H., Noll M., Jones D.B. Mechanosensitivity of human osteosarcoma cells and phospholipase C beta2 expression. Biochem Biophys Res Commun 2005, 333(1):142-149.
5. Wang Y., Wan C., Deng L., Liu X., Cao X., Gilbert S.R., et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 2007, 117(6):1616-1626.
6. Thi M.M., Iacobas D.A., Iacobas S., Spray D.C. Fluid shear stress up-regulates vascular endothelial growth factor gene expression in osteoblasts. Ann N Y Acad Sci 2007.
7. Faure C., Linossier M.T., Malaval L., Lafage-Proust M.H., Peyroche S., Vico L., et al. Mechanical signals modulated vascular endothelial growth factor-A (VEGF-A) alternative splicing in osteoblastic cells through actin polymerisation. Bone 2008, 42(6):1092-1101.
8. Dumas V., Perrier A., Malaval L., Laroche N., Guignandon A., Vico L., et al. The effect of dual frequency cyclic compression on matrix deposition by osteoblast-like cells grown in 3D scaffolds and on modulation of VEGF variant expression. Biomaterials 2009, 30(19):3279-3288.
9. Ferrara N., Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999, 5(12):1359-1364.
10. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4(12):1317-1326.
11. Mayr-Wohlfart U., Waltenberger J., Hausser H., Kessler S., Gunther K.P., Dehio C., et al. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 2002, 30(3):472-477.
12. Witmer A.N., van Blijswijk B.C., van Noorden C.J., Vrensen G.F., Schlingemann R.O. In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. J Histochem Cytochem 2004, 52(1):39-52.
13. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87(8):3336-3343.
14. Tombran-Tink J., Barnstable C.J. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. Biochem Biophys Res Commun 2004, 316(2):573-579.
15. Aldridge S.E., Lennard T.W., Williams J.R., Birch M.A. Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br J Cancer 2005, 92(8):1531-1537.
16. Nakagawa M., Kaneda T., Arakawa T., Morita S., Sato T., Yomada T., et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000, 473(2):161-164.
17. Spyridopoulos I., Brogi E., Kearney M., Sullivan A.B., Cetrulo C., Isner J.M., et al. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J Mol Cell Cardiol 1999, 29(5):1321-1330.
18. Gerber H.P., Dixit V., Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998, 273(21):13313-13316.
19. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273(46):30336-30343.
20. Chen T.T., Luque A., Lee S., Anderson S.M., Segura T., Iruela-Arispe M.L. Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. J Cell Biol 2010, 188(4):595-609.
21. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. The J Cell Biol 2005, 169(4):681-691.
22. Anderson S.M., Chen T.T., Iruela-Arispe M.L., Segura T. The phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) by engineered surfaces with electrostatically or covalently immobilized VEGF. Biomaterials 2009, 30(27):4618-4628.
23. Kaigler D., Wang Z., Horger K., Mooney D.J., Krebsbach P.H. VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects. J Bone Miner Res 2006, 21(5):735-744.
24. Geiger F., Bertram H., Berger I., Lorenz H., Wall O., Eckhardt C., et al. Vascular endothelial growth factor gene-activated matrix (VEGF 165-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. J Bone Miner Res 2005, 20(11):2028-2035.
25. Thevenaz P., Blu T., Unser M. Interpolation revisited. IEEE Trans Med Imaging 2000, 19(7):739-758.
26. Hennequin L.F., Thomas A.P., Johnstone C., Stokes E.S., Ple P.A., Lohmann J.J., et al. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 1999, 42(26):5369-5389.
27. Wijelath E.S., Murray J., Rahman S., Patel Y., Ishida A., Strand K., et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Cir Res 2002, 91(1):25-31.
28. Stringer S.E. The role of heparan sulphate proteoglycans in angiogenesis. Biochem Soc Trans 2006, 34(Pt 3):451-453.
29. Rousseau S., Houle F., Kotanides H., Witte L., Waltenberger J., Landry J., et al. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 2000, 275(14):10661-10672.
30. Folkman J., Klagsbrun M. Vascular physiology. A family of angiogenic peptides. Nature 1987, 329(6141):671-672.
31. Ortega N., Hutchings H., Plouet J. Signal relays in the VEGF system. Front Biosci 1999, 4:D141-D152.
32. Herve M.A., Buteau-Lozano H., Mourah S., Calvo F., Perrot-Applanat M. VEGF189 stimulates endothelial cells proliferation and migration in vitro and up-regulates the expression of Flk-1/KDR mRNA. Exp Cell Res 2005, 309(1):24-31.
33. Richardson T.P., Peters M.C., Ennett A.B., Mooney D.J. Polymeric system for dual growth factor delivery. Nat Biotechnol 2001, 19(11):1029-1034.
34. Seliktar D., Zisch A.H., Lutolf M.P., Wrana J.L., Hubbell J.A. MMP-2 sensitive, VEGF-bearing bioactive hydrogels for promotion of vascular healing. J Biomed Mater Res A 2004, 68(4):704-716.
35. Kaliski A., Maggiorella L., Cengel K.A., Mathe D., Rouffiac V., Opolon P., et al. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther 2005, 4(11):1717-1728.
36. Sounni N.E., Roghi C., Chabottaux V., Janssen M., Munaut C., Maquoi E., et al. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 2004, 279(14):13564-13574.
37. Seo D.W., Li H., Guedez L., Wingfield P.T., Diaz T., Salloum R., et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003, 114(2):171-180.
38. Fernandez-Garcia N.I., Volpert O.V., Jimenez B. Pigment epithelium-derived factor as a multifunctional antitumor factor. J Mol Med 2007, 85(1):15-22.
39. Filleur S., Nelius T., de Riese W., Kennedy R.C. Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem 2009, 106(5):769-775.
40. Ancelin M., Buteau-Lozano H., Meduri G., Osborne-Pellegrin M., Sordello S., Plouet J., et al. A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability in human uterus. Proc Natl Acad Sci U S A 2002, 99(9):6023-6028.
41. Herve M.A., Buteau-Lozano H., Vassy R., Bieche I., Velasco G., Pla M., et al. Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. Am J Pathol 2008, 172(1):167-178.
42. Ozawa C.R., Banfi A., Glazer N.L., Thurston G., Springer M.L., Kraft P.E., et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004, 113(4):516-527.
43. von Degenfeld G., Banfi A., Springer M.L., Wagner R.A., Jacobi J., Ozawa C.R., et al. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. Faseb J 2006, 20(14):2657-2659.
44. Midy V., Hollande E., Rey C., Dard M., Plouet J. Adsorption of vascular endothelial growth factor to two different apatitic materials and its release. J Mater Sci Mater Med 2001, 12(4):293-298.
45. Zeng H., Dvorak H.F., Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 2001, 276(29):26969-26979.